Skip to main content

Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?

Annals of Surgical Oncology volume 13, pages 1379–1385 (2006)Cite this article

Abstract

Background

Combination chemotherapy using oxaliplatin, 5-fluorouracil and folinic acid (FOLFOX) is known to be effective in the treatment of metastatic colon cancer. Genes regulating the actions of 5-fluorouracil and oxaliplatin have been identified, but precisely which gene is dominant has not yet been determined. The aim of the investigation reported here was to identify which gene polymorphism is a dominant factor in FOLFOX chemotherapy–the methylenetetrahydrofolate reductase (MTHFR) gene for 5-fluorouracil or the X-ray cross-complementing1 (XRCC1) gene for oxaliplatin.

Methods

Paraffin-embedded tissues from 54 patients with unresectable metastases from colorectal cancer who had undergone chemotherapy with the FOLFOX regimen were analyzed for MTHFR polymorphisms in the MTHFR gene (677C➔T, Ala➔Val mutation) and XRCC1 gene (Arg➔Gln substitution in exon 10). Response rates and survivals were compared by types of polymorphism.

Results

Analyses of the patterns of MTHFR polymorphism revealed that 29.6% of the patients showed no mutation, 51.6% showed heterozygous mutations, and 11.8% showed homozygous mutations. Analyses of the XRCC1 polymorphism revealed that 60.8% of the patients showed no mutation, 31.4% showed heterozygous mutations, and 7.8% showed homozygous mutations. After four cycles of chemotherapy, 3.7% showed a complete response, 57.4% showed a partial response (PD) or stable disease, and 38.9% showed PD. The MTHFR polymorphism was not significant in predicting response and 30-month-survival (P > .1), whereas the XRCC1 polymorphism was a significant prognostic factor for both response (P = .038) and survival (P = .011).

Conclusions

We found a higher rate of mutations in the MTHFR gene than in the XRCC1 gene in Korean colorectal cancer patients. Response to FOLFOX was better in the patient group with mutations for MTHFR and worse in the patient group with mutations for XRCC1. However, only the XRCC1 polymorphism was a significant prognostic factor for the response to FOLFOX chemotherapy and short-term survival.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1.
Fig. 2.
Fig. 3.

References

  1. Okumura K, Shiomi H, Mekata E, Kaizuka M, Kurumi Y, Tani T. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 2006; 15:875–882

    CAS  PubMed  Google Scholar 

  2. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and clinical biomarkers in drug discovery and development. Am J Clin Pathol 2005; 124(Suppl):S29–41

    CAS  PubMed  Google Scholar 

  3. van Triest B, Pinedo HM, Blaauwgeers JL, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000; 6:1063–1072

    PubMed  Google Scholar 

  4. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298–4304

    CAS  PubMed  Google Scholar 

  5. Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005; 23:4545–4552

    CAS  Article  PubMed  Google Scholar 

  6. Yamayoshi Y, Iida E, Tanigawara Y. Cancer pharmacogenomics: international trends. Int J Clin Oncol 2005; 10:5–13

    Article  PubMed  Google Scholar 

  7. Etienne MC, Formento JL, Chazal M, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14:785–792

    CAS  Article  PubMed  Google Scholar 

  8. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz H-J. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91:344–354

    CAS  PubMed  Google Scholar 

  9. Suh KW, Kim JH, Kim YB, Kim J, Jeong S. Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J Gastrointest Surg 2005; 9:336–342

    Article  PubMed  Google Scholar 

  10. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005; 10 Suppl 3:40–48

    CAS  Article  PubMed  Google Scholar 

  11. Saltz LB. Metastatic colorectal cancer: is there one standard approach? Oncology 2005; 19:1147–1154

    PubMed  Google Scholar 

  12. de Gramont A, Figer A, Seymour M, et al. Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–2947

    PubMed  Google Scholar 

  13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leukovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23–30

    CAS  Article  PubMed  Google Scholar 

  14. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leukovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136–147

    CAS  PubMed  Google Scholar 

  15. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25:4–12

    CAS  PubMed  Google Scholar 

  16. Cohen V, Raymond VP, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9:1611–1615

    CAS  PubMed  Google Scholar 

  17. Stoehlmacher J, Ghaderi V, Iqval S, Groshen S, Tsao-wei D, Park D, Lenz HJ. A polymorphsim of xrcc1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21:3075–3080

    CAS  PubMed  Google Scholar 

  18. Scheele J, Stang R, Altendorf-Hofman A, Paul M. Resection of colorectal liver metastasis. World J Surg 1995; 19:59–71

    CAS  Article  PubMed  Google Scholar 

  19. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–321

    CAS  Article  PubMed  Google Scholar 

  20. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 2005; 23:4553–4560

    CAS  Article  PubMed  Google Scholar 

  21. Balasubramanian SP, Cox A, Brown NJ, Reed MW. Candidate gene polymorphism in solid cancers. Eur J Surg Oncol 2004; 30:593–601

    CAS  Article  PubMed  Google Scholar 

  22. Liu Z, Lin S. Multilocus LD measure and tagging SNP selection with generalized mutual information. Genet Epidemiol 2005; 29:353–364

    Article  PubMed  Google Scholar 

  23. Sanguedolce R, Vultaggio G, Sanguedolce F, et al. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 1998; 18:1515–1520

    CAS  PubMed  Google Scholar 

  24. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumor responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322–1327

    CAS  PubMed  Google Scholar 

  25. Little J, Sharp L, Duthie S, Narayanan S. Colon cancer and genetic variation in folate metabolism: the clinical bottom line. J Nutr 2003; 133[Suppl 11]:3758–66s

    Google Scholar 

  26. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:285–92

    CAS  Article  PubMed  Google Scholar 

  27. Mani RS, Karimi-Busher F, Fanta M, Caldecott KW, Cass CE, Weinfield M. Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA. Biochemistry 2004; 43:16505–14

    CAS  Article  PubMed  Google Scholar 

  28. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia JM, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998; 18:3563–3571

    CAS  PubMed  Google Scholar 

  29. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94:7303–7307

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Surgery, Ajou University School of Medicine, Suwon, 442-749, Korea

    Kwang Wook Suh MD, Joo Hyung Kim MD & Do Yoon Kim MD

  2. Department of Pathology, Ajou University School of Medicine, Suwon, Korea

    Young Bae Kim MD

  3. ISU ABIXIS Co., Ltd., Seoul, Korea

    Chulho Lee & Sungho Choi PhD

Authors
  1. Kwang Wook Suh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joo Hyung Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Do Yoon Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Young Bae Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chulho Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sungho Choi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kwang Wook Suh MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Suh, K.W., Kim, J.H., Kim, D.Y. et al. Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?. Ann Surg Oncol 13, 1379–1385 (2006). https://doi.org/10.1245/s10434-006-9112-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-006-9112-y

Keywords

  • Metastatic colon cancer
  • FOLFOX
  • XRCC1
  • MTHFR
  • Gene polymorphism